Prosperity Financial Group Inc. Raises Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Prosperity Financial Group Inc. increased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,137 shares of the medical equipment provider’s stock after acquiring an additional 464 shares during the quarter. Prosperity Financial Group Inc.’s holdings in Lantheus were worth $454,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares during the last quarter. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 100 shares during the last quarter. UMB Bank n.a. increased its position in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC raised its stake in Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after acquiring an additional 146 shares during the last quarter. Finally, Moody National Bank Trust Division lifted its position in Lantheus by 1.1% during the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after acquiring an additional 162 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 3.7 %

Shares of LNTH stock opened at $90.52 on Monday. The stock has a market cap of $6.29 billion, a P/E ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The business has a fifty day simple moving average of $103.13 and a 200-day simple moving average of $96.93.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several analyst reports. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Finally, JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.